London, July 8, 2026, 18:05 BST
- EDX Medical Group PLC LON:EDX gained 3.03% to 8.50p on volume of 166,509 shares after the company put out a morning RNS about a service deal with Astron Health.
- EDX Medical is adding a UK molecular profiling path for cancer second opinions under a new deal, but didn’t share any financial details.
- The company is valued at £35.02 million, with forecast FY2026 revenue around £1.2 million, so the stock continues to trade at an early-stage diagnostics multiple.
London stocks closed for the day at 18:05 BST, following the usual London Stock Exchange hours of 8:00 to 16:30. EDX Medical Group PLC LON:EDX finished up. Most UK shares fell, so the move looked specific to the company, not the index.
EDX announced Astron Health picked it to supply molecular profiling products and services in the UK. The release listed Caris MI Profile, used for tumour profiling, and Caris Assure, a blood-based test for solid tumours when tissue can’t be biopsied.
| July 8 market read | Level / move |
|---|---|
| EDX Medical | 8.50p, up 3.03%; volume at 166,509 |
| EDX quoted spread | Sell at 8.50p / buy at 9.50p |
| FTSE AIM All-Share | 758.07, down 1.44% |
| FTSE 100 | 10,489.04, off 1.66% |
The move is bigger than it seems on first look. EDX traded up during a weak London session, though the 1p quoted spread is wide for an 8.50p sale. On AIM microcaps, that makes a difference. A 3% swing can be both true and choppy.
Investors had nothing on contract value. The release didn’t list financial terms or say when the deal starts, according to Investing.com. So the Astron agreement is mostly about distribution and profile for now, not revenue.
Professor Sir Chris Evans, founder of EDX, said Astron picked EDX to give it “the most advanced and detailed cancer tests.” Dr Padman Vamadevan, Astron’s co-founder and chief medical officer, said clinicians and patients need access to “best-in-class diagnostic tests.” Investegate
| Valuation check | Read-through |
|---|---|
| Market cap | £35.02 million |
| Forecast revenue, year ending March 31, 2026 | Roughly £1.2 million |
| Market cap to expected revenue | Nears 29 times |
| Stock price vs Feb 14p raise | Trading about 39% under |
| Value change on 0.25p move | Gain of about £1.0 million, based on 411,994,583 shares |
This is the takeaway for investors. The market tacked on about £1 million in paper value to a deal where no size was disclosed. That’s not huge for a diagnostics firm trying to show it can access markets, but it does point to the importance of future contract details.
The main valuation question is the gap between where shares trade and the price those investors paid in the last round. Back in February, high-net-worth backers picked up 24,999,999 shares at 14p, raising £3.5 million. But now the shares are selling at 8.50p, a sharp drop from that level.
Cash is still there, but the risk of dilution is still in play. Back in April, EDX put out numbers showing it was expecting about £1.2 million in revenue for the year to March 31, 2026, had closed that period with around £2.9 million cash, and had a working capital line from Evans up to £3.71 million on top of an existing £2.0 million convertible loan. That same filing said EDX planned to keep raising equity after getting on AIM.
The share register lays out who owns what in the stock. EDX reported that 37.70% of its shares are in public hands. Evans has 33.06%, Bridgemere Securities 9.46%, West Coast Capital 7.63%, Countywide Development 6.64%, and CEO Dr Michael Hudson 5.01%. A limited free float can make the stock swing harder in either direction.
EDX shifted from Aquis to AIM in May, looking for more capital, better investor visibility and higher trading liquidity. Now the company has to prove that being on AIM can help convert its lab assets and distribution deals into big enough orders to move the needle for a £35 million market cap.
The Companies House website says the next set of accounts, up to March 31, 2026, are due by Sept. 30. For now, investors rely on company guidance, RNS language and what little trading comes through each day.
